FRESENIUS MEDICAL CARE-ADR
FMSNYSETrading Snapshot
- Day Range
- $22.06 β $22.56
- 52-Week Range
- $20.02 β $27.64
- Volume
- $2.43B
- Avg Volume
- $2.26B
- Shares Outstanding
- 537.1M
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $19.63B
- Last Q Revenue
- $4.86B
- P/E Ratio
- 11.8
- P/S Ratio
- 0.5x
- EPS (TTM)
- $1.75
- Dividend Yield
- 3.80%
- Dilution (1yr)
- β51.3%
Why Investors Own FMS
- βHigh-growth profile β revenue up -7.6% YoY with expanding US Equity exposure.
- βHealthy economics β 58% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FRESENIUS MEDICAL CARE-ADR
FMSAbout FRESENIUS MEDICAL CARE-ADR
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) has received an average recommendation of "Reduce" from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in re

Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS
Tidal Investments LLC grew its stake in shares of Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) by 96.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exch

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.